Back to search

Switzerland· 65041005

Xultophy Insulin Degludec 100 E/ml und Liraglutide 3.6 mg/ml, Injektionslösung

A insulin degludec and liraglutide product containing insulinum degludecum, liraglutidum, registered in Switzerland by Novo Nordisk Pharma AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC A10AE56

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedXultophy Insulin Degludec 100 E/ml un…ATCA10AE56REGISTER NO.65041005PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Insulin degludec and liraglutide is registered in 12 of 19 countries.

Countries holding a registration under ATC A10AE56 (insulin degludec and liraglutide), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Insulin degludec and liraglutide · ATC A10AE56

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
insulinum degludecum, liraglutidum
Manufacturer
Novo Nordisk Pharma AG
Country
Switzerland (CH)
ATC code
A10AE56
ATC class
Insulin degludec and liraglutide
Defined daily dose
40 E, P
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680650410058
    3 Fertpen 3 ml
    CHF 143.55

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Insulin degludec and liraglutide in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All insulin degludec and liraglutide products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Iceland · Xultophy
  • Norway · Xultophy

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b1a0a042-ace7-4ea2-b68a-3c6ff4aa0688
GET /v1/drugs/b1a0a042-ace7-4ea2-b68a-3c6ff4aa0688?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "insulinum degludecum 100 U + liraglutidum 3.6 mg",
  "valid_from": "2014-11-01",
  "limitations": "[{\"description\":\"Xultophy wird in Kombination mit Metformin oder mit Metformin plus einem Sulfonylharnstoff zur Behandlung des Typ 2 Diabetes mellitus bei Erwachsenen angewendet, wenn Metformin allein, Metformin in Kombination mit einem Sulfonylharnstoff oder Metformin in Kombination mit einem Basalinsulin keine adäquate Blutzuckerkontrolle gewährleisten.<br>\\nMindestens BMI 28.<br>\\nZusätzliche Medikamente zur Gewichtsreduktion werden nicht vom Krankenversicherer vergütet.\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2014-11-01\"}]",
  "galenic_form": "Inj Lös 100E/ml 3.6 mg/ml",
  "therapeutic_area": null,
  "sl_inclusion_date": "2014-11-01",
  "self_retention_pct": 10
}

See everything about insulin degludec and liraglutide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.